Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C

October 21, 2010 By Bio-Medicine.Org

VIENNA, Oct. 21 /PRNewswire/ — Intercell AG (VSE; “ICLL”) and
Romark Laboratories L.C. today announced plans to commence clinical
trials of Intercell’s investigational therapeutic Hepatitis C virus
(HCV) vaccine, IC41, in combination with Romark’s antiviral drug,
nitazoxanide, during the first half of 2011.

Intercell’s vaccine candidate has demonstrated a sustained
reduction of viral load in chronic Hepatitis C (CHC) patients in a
Phase II proof-of-concept trial. Nitazoxanide is an oral therapy
that targets host cell factors involved in HCV replication and is
not associated with viral mutations conferring resistance.
Nitazoxanide has been shown to induce sustained virologic response
as monotherapy in some patients chronically infected with HCV.

The planned European Phase II trial will include about 60
treatment-naïve patients chronically infected with HCV
genotype-1 in three treatment arms: (1) IC41 plus nitazoxanide, (2)
IC41 plus nitazoxanide and Pegasys® (peginterferon alfa-2a) and
(3) Pegasys and Copegus® (ribavirin), the current standard of
care, as an active control. The primary endpoint will be sustained
virologic response (no detectable HCV RNA 24 weeks after
end-of-treatment).

The companies involved in the combination study will retain
commercial rights for their respective products.

“We are very pleased about this important next step in the
development of our vaccine candidate against Hepatitis C. The
distinctly different mode-of-action and the outstanding
tolerability of both treatments create a joint approach in a field
that will continue to have high unmet medical need over the next
decades,” stated Gerd Zettlmeissl, CEO of Intercell.

“We are excited about this novel therapeutic approach for
chronic Hepatitis C,” said Jean-Francois Rossignol, M.D., Ph.D.,
Chairman and Chief Science Officer of Romark. “There is an
important need for novel therapies that offer improvements in
safety and efficacy com

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech